Alzheimer's hope strands at US Biohaven
Biohaven has failed its trial program with a treatment for Alzheimer's disease in phase II-III, but hopes follow-up analyses will have promising outcome, so the firm will not have to ditch the drug.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Like Danish Lundbeck, US biotech company Biohaven has had successful migraine treatments, but just like the Danish firm it has had some difficulty with other parts of its pipeline.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo ceases payments to US politicians
For abonnenter
